Julie Kim is president of the U.S. Business Unit and U.S. country head at Takeda. The U.S. Business Unit portfolio encompasses gastroenterology, neuroscience, plasma-derived therapies, and rare diseases. Previously, she was president of Takeda’s Plasma-Derived Therapies Business Unit. Her 30 years of experience in health care includes global, regional, country, and functional leadership positions spanning a variety of therapeutic areas, international market access, country and regional general management, marketing, and emerging market development. She is on the board of directors of Croda International Plc, a company using smart science to create high-performance ingredients and technologies that improve lives. Kim was one of Boston’s 50 Most Influential Asian American Pacific Islanders in 2023, on the 2022 PharmaVoice 100 list, and on Fierce Pharma’s list of 2020’s Fiercest Women in Life Sciences. (Takeda is a 2024 Festival Underwriter)
Previously
Eighty percent of what impacts our health happens outside of the doctor's office: from education and employment opportunities to access to housing, transportation, and quality...